Email this article Clinical efficacy of acute respiratory viral infections prevention in patients with chronic heart failure
- Authors: Budnevsky AV1, Shurupova AD1, Kravchenko AY.1, Tokmachev RE1
-
Affiliations:
- Voronezh State Medical University of the Ministry of Health of the Russian Federation
- Issue: Vol 91, No 3 (2019)
- Pages: 36-41
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/33010
- DOI: https://doi.org/10.26442/00403660.2019.03.000111
- ID: 33010
Cite item
Full Text
Abstract
The aim of the study was to evaluate the ARVI prevention effectiveness in patients with chronic heart failure (CHF) using interferon inducer amixin. Materials and methods. Conducted a comprehensive survey, dynamic monitoring and treatment of 60 patients aged from 49 to 70 years (mean age 60.25±4.57 years, 17 men and 43 women) with CHF with preserved ejection fraction of left ventricle (LVEF) (≥50%), II-III functional class (FC) according to the classification of new York Heart Association (NYHA), which developed as a result of coronary heart disease (CHD), hypertensive disease (HD). Of these, 30 patients (group 1) on the background of standard therapy for CHF received for the prevention of ARVI tiloron (Amixin) at a dose of 125 mg once a week for 6 weeks, two courses for 1 year. Group 2 patients received only standard therapy for CHF. Results. A decrease in the frequency of ARVI in patients with CHF treated with Amixin was found, which was accompanied by a decrease in the severity of subclinical inflammation by reducing the production of proinflammatory (IL-1β) and increasing the production of anti-inflammatory (IL-10) cytokines, reducing neurohumoral activation (reducing levels of aldosterone and Nt-proBNP), increasing the level of α- and γ-interferon. The positive dynamics of biomarkers of systemic inflammation and neurohormonal activation explains the improvement of the clinical course in patients with CHF (increase of tolerance to physical loads, reducing the number of visits to General practitioner and hospital admissions in the hospital during 12 months of observation). Conclusion. A promising approach to the prevention of SARS in patients with CHF is course therapy with Amixin (2 times a year before the seasonal rising in the incidence of respiratory viral infections and influenza), which allows to achieve both decreasing in the frequency of SARS per year, and improvement the clinical course of CHF.
Full Text
##article.viewOnOriginalSite##About the authors
A V Budnevsky
Voronezh State Medical University of the Ministry of Health of the Russian Federationд.м.н., проф., зав. каф. факультетской терапии; ORCID: 0000-0002-1171-2746 Voronezh, Russia
A D Shurupova
Voronezh State Medical University of the Ministry of Health of the Russian Federationаспирант каф. факультетской терапии; ORCID: 0000-0002-5696-850X Voronezh, Russia
A Ya Kravchenko
Voronezh State Medical University of the Ministry of Health of the Russian Federationд.м.н., проф. каф. факультетской терапии; ORCID: 0000-0003-0297-1735 Voronezh, Russia
R E Tokmachev
Voronezh State Medical University of the Ministry of Health of the Russian Federation
Email: r-tokmachev@mail.ru
к.м.н., ассистент каф. факультетской терапии Воронежского государственного медицинского университета им. Н.Н. Бурденко; тел.: +7(900)300-30-13; e-mail: r-tokmachev@mail.ru; ORCID: 0000-0001-6379-4635 Voronezh, Russia
References
- Фомин И.В. Хроническая сердечная недостаточность в Российской Федерации: что сегодня мы знаем и что должны делать. Российский кардиологический журнал. 2016;(8):7-13. doi: 10.15829/1560-4071-2016-8-7-13
- Tokmachev R.E, Budnevsky A.V, Kravchenko A.Ya. The possibility of non - pharmacological methods in increasing clinical efficiency of treating patients with chronic heart failure and metabolic syndrome. Research Journal of Pharmaceutical, Biological and Chemical Sciences. 2017;8(6):832-9.
- Shiryaev O.Yu, Yankovskaya V.L, Budnevsky A.V, Ovsyannikov E.S. Psychosomatic aspects of chronic heart failure. International Journal of Biomedicine. 2017;7(3):248-50. doi: 10.21103/Article7(3)_ShC1
- Рекомендации ESC по диагностике и лечению острой и хронической сердечной недостаточности 2016. Российский кардиологический журнал. 2017;(1):7-81. doi: 10.15829/1560-4071-2017-1-7-81
- Беленков Ю.Н., Мареев В.Ю., Агеев Ф.Т., Фомин И.В. и др. Истинная распространенность ХСН в Европейской части Российской Федерации (исследование ЭПОХА, госпитальный этап). Сердечная Недостаточность. 2011;2(64):63-8. doi: 10.18087/rhfj.2011.2.1510
- Калягин А.Н. Возможности предупреждения декомпенсации хронической сердечной недостаточности за счет применения вакцин против возбудителей респираторных инфекций. Сибирский медицинский журнал (Иркутск). 2008;7:46-8.
- Калягин А.Н. Хроническая сердечная недостаточность: современное состояние проблемы. Факторы риска декомпенсации (сообщение 6). Сибирский медицинский журнал (Иркутск). 2006;66(8):84-8.
- Van Linthout S, Tschöpe C. Inflammation - Cause or Consequence of Heart Failure or Both? Curr Heart Fail Rep. 2017;14(4):251-65. doi: 10.1007/s11897-017-0337-9
- Davis M, Taubert K, Benin A, et al. Influenza vaccination as secondary prevention for cardiovascular disease: a science advisory from the American Heart Association/American College of Cardiology. Circulation. 2006;114(14):1549-53. doi: 10.1161/circulationaha.106.178242
- Косенко И.М. Профилактика и лечение острых респираторных вирусных инфекций. Медицинский совет. 2014;15:6-11.
- Gupta P, Boro A. Precipitating factors leading to decompensation in patient with chronic heart failure. Indian Heart J. 2017;69:S85. doi: 10.1016/j.ihj.2017.09.101
- Kladova O, Molochkova O, Waltz N, Kompaniets Y, Grishkevich N. The Value of the Interferon Inductors in the Treatment and Prevention of Respiratory Infections. Children infections. 2016;15(4):48-53. doi: 10.22627/2072-8107-2016-15-4-48-53
- Huang L, Zhang L, Liu Y, et al. Arbidol for preventing and treating influenza in adults and children. Cochrane Database of Systematic Reviews. 2017. doi: 10.1002/14651858.cd011489.pub2
